13/03/2018 20:30:39

ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference

ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference

Lyon (France), March 13, 2018

- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at The Marriott Copley Place, in Boston, MA.

Conference Details:

  • Conference: Cowen and Company 38th Annual Health Care Conference
  • Date: March 14, 2018
  • Presentation Time: 9:20 AM EDT / 14:20 CET

A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://erytech.com/webcast.html and via the below link: http://wsw.com/webcast/cowen46/eryp/

Following, the live webcast, an archive of the presentation will be available on the company website for 30 days, under the "Investors" section at investors.erytech.com.

About ERYTECH and eryaspase (GRASPA®):

www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-gamma-lyase encapsulated in red blood cells, to target cancer cells' amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS 

ERYTECH    

Naomi Eichenbaum

Director of Investor Relations

The Ruth Group

Lee Roth

Investor relations

Kirsten Thomas

Media relations

NewCap

Julien Perez

Investor relations

Nicolas Merigeau

Media relations

 

+33 4 78 74 44 38

+1 917 312 5151

naomi.eichenbaum@erytech.com

 

+1 646 536 7012

lroth@theruthgroup.com

+1 508 280 6592

kthomas@theruthgroup.com

 

+33 1 44 71 98 52 erytech@newcap.eu

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Jun
I:SP500
  Hejsa alle sammen   Konjunktur: Ifølge vedlagte teoretiske model omkring de ledende indikatorer be..
48
20 Jun
GEN
Et gammelt indlæg:   Hvis man kigger lidt tilbage i tiden og ser på de kvartalsvise resultater, så l..
36
18 Jun
PNDORA
              Jeg har lavet en fuld analyse på Pandora, som er en blanding af en regnskabs-analyse o..
17
20 Jun
GEN
Hold da kæft, du er godt nok en sur (gammel ?) mand......
16
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
19 Jun
I:SP500
Trump har bedt det amerikanske handelsministerie om en liste over kinesiske varer for 200 mia USD, s..
12
18 Jun
BAVA
Dvs de bør være der indenfor 9 børsdage... Hvis disse data gentager det som er kommet frem indtil nu..
12
23 Jun
 
USA blev løftet ud af recession under Obama. Punktum. Økonomien kørte fint da Trump blev valgt og er..
11
20 Jun
NOVO-B
Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenl..
11
18 Jun
VWS
I begyndelse af året havde grædekonerne kronede dage, hvad angår ordreindtag. Det har li'som ændret ..
11

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
2
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
3
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
4
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 04:27:27
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB7 - 2018-06-24 05:27:27 - 2018-06-24 04:27:27 - 1000 - Website: OKAY